A5023398890- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Biochemical and Structural Characterization
- Cell Adhesion Molecules Research
- Autophagy in Disease and Therapy
- CRISPR and Genetic Engineering
- Viral Infectious Diseases and Gene Expression in Insects
- GDF15 and Related Biomarkers
- Nutrition and Health in Aging
- Angiogenesis and VEGF in Cancer
- Nanofabrication and Lithography Techniques
Ludwig Cancer Research
2019-2025
University of Lausanne
2019-2025
Molecular Partners (Switzerland)
2012-2017
MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), anti-hepatocyte factor (HGF), and two anti-human serum albumin (HSA) DARPin® domains within single polypeptide chain. While there first validation single-domain candidate, little known about candidates comprising multiple domains. Here, we show that can be expressed at 15 g/L soluble form E. coli high cell-density...
Macroautophagy (autophagy hereafter) captures intracellular components and delivers them to lysosomes for degradation recycling 1 . In adult mice, autophagy sustains metabolism prevent wasting by cachexia survive fasting, also suppresses inflammation, liver steatosis, neurodegeneration, lethality 2,3 Defects in contribute metabolic, inflammatory degenerative diseases, however, the specific mechanisms involved were unclear 4 Here we profiled inflammation mice with conditional, whole-body...
Background The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous patient T cells via engineered anti-MSLN chimeric antigen receptors (CAR-T) approach garnering considerable interest. Although generally shown to tumor MSLN safely, CAR-T trials have failed deliver impressive curative or...
Abstract An early bottleneck in the rapid isolation of new antibody fragment binders using vitro library approaches is inertia encountered acquiring and preparing soluble antigen fragments. In this report, we describe a simple, yet powerful strategy that exploits properties SpyCatcher/SpyTag (SpyC/SpyT) covalent interaction to improve substantially speed efficiency obtaining functional clones interest. We demonstrate SpyC has broad utility as protein-fusion tag partner eukaryotic...
Tumor endothelial marker 1 (TEM1) is an emerging cancer target with a unique dual expression profile. First, TEM1 expressed in the stroma and neo-vasculature of many human carcinomas but largely absent from healthy adult tissues. Second, by tumor cells mesenchymal origin, notably sarcoma. Here, we present two fully anti-TEM1 single-chain variable fragment (scFv) reagents, namely, 1C1m 7G22, that recognize distinct regions extracellular domain possess substantially different affinities. In...
Abstract Anti-tumor therapies that seek to exploit and redirect the cytotoxic killing effector potential of autologous or syngeneic T cells have shown extraordinary promise efficacy in certain clinical settings. Such cells, when engineered express synthetic chimeric antigen receptors (CARs) acquire novel targeting activation properties which are governed orchestrated by, typically, antibody fragments specific for a tumor interest. However, it is becoming increasingly apparent not all...